Cargando…

Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel Perspective

SIMPLE SUMMARY: Small cell lung cancer (SCLC) continues to carry a poor prognosis with a five-year survival rate of 3.5% and a 10-year survival rate of 1.8%. The pathogenesis remains unclear, and there are no known predictive or diagnostic biomarkers. The current SCLC classification as a single enti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denninghoff, Valeria, Russo, Alessandro, de Miguel-Pérez, Diego, Malapelle, Umberto, Benyounes, Amin, Gittens, Allison, Cardona, Andres Felipe, Rolfo, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038650/ https://www.ncbi.nlm.nih.gov/pubmed/33917282 http://dx.doi.org/10.3390/cancers13071723

Ejemplares similares

The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution?
por: Rolfo, Christian, et al.
Publicado: (2023)

Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
por: Cortinovis, Diego, et al.
Publicado: (2021)

Targeted therapy and non-small cell lung cancer: a new era!
por: Malapelle, Umberto, et al.
Publicado: (2019)

A New Generation of Vaccines in the Age of Immunotherapy
por: Addeo, Alfredo, et al.
Publicado: (2021)

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
por: Chamorro, Diego F., et al.
Publicado: (2023)

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
por: Garcia-Robledo, Juan Esteban, et al.
Publicado: (2022)

Immunotherapy Resistance in Non-Small Cell Lung Cancer: A Rubik's Cube to Assemble
por: Rolfo, Christian, et al.
Publicado: (2021)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
por: Malapelle, Umberto, et al.
Publicado: (2017)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Landscape into art
por: Clark, Kenneth, 1903-1983

Landscape into art /
por: Clark, Kenneth, 1903-1983
Publicado: (1949)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
por: Malapelle, Umberto, et al.
Publicado: (2022)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
por: Reclusa, Pablo, et al.
Publicado: (2019)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
por: Crocetto, Felice, et al.
Publicado: (2022)

Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy
por: Cammarata, Giuseppe, et al.
Publicado: (2022)

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2021)

Small Cell Lung Cancer: A New Era Is Beginning?
por: Morabito, Alessandro, et al.
Publicado: (2021)

Brave new world of cfDNA-omics for early cancer detection
por: Rolfo, Christian, et al.
Publicado: (2023)

How I treat ALK-positive non-small cell lung cancer
por: McCusker, Michael G, et al.
Publicado: (2019)

Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
por: Vigliar, Elena, et al.
Publicado: (2021)

Generative Art with Swarm Landscapes
por: de Andrade, Diogo, et al.
Publicado: (2020)

USP11 role in colorectal cancer growing and metastatisation
por: Malapelle, Umberto
Publicado: (2019)

Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer
por: de Miguel-Perez, Diego, et al.
Publicado: (2023)

Informational Landscapes in Art, Science, and Evolution
por: Cohen, Irun R.
Publicado: (2006)

The molecular landscape of breast mucoepidermoid carcinoma
por: Venetis, Konstantinos, et al.
Publicado: (2023)

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
por: Attili, Ilaria, et al.
Publicado: (2022)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib
por: Malapelle, Umberto, et al.
Publicado: (2022)

Editorial: Molecular pathology and computational image analyses in gynecologic malignancies
por: Malapelle, Umberto, et al.
Publicado: (2022)

Editorial: Long non-coding RNAs in lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2022)

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies
por: Zhang, Peng, et al.
Publicado: (2020)

Understanding EGFR heterogeneity in lung cancer
por: Passaro, Antonio, et al.
Publicado: (2020)

The landscape perspective /
Publicado: (1995)

Exhaled breath analysis in hepatology: State-of-the-art and perspectives
por: De Vincentis, Antonio, et al.
Publicado: (2019)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
por: Friedlaender, Alex, et al.
Publicado: (2020)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gms7508ltut7666h8bas32ojn0